ImmueMed
Contact Us
KO
Company
Company Introduction
CEO Greeting
Organizational Status
Management Goals
Direction
Products
Diagnostic Kits
Antiviral agent (VSF)
Products Under Development
R & D
Antiviral Agent
Infectious Diseases
Research Projects
Pipeline
Company News
Publicity
Exhibition
Investment Information
Notice
Financial Information
Investment Inquiry
Company
Company Introduction
CEO Greeting
Organizational Status
Management Goals
Direction
Products
Diagnostic Kits
Antiviral Agent (VSF)
Products Under Development
R & D
Antiviral Agent
Infectious Diseases
Research Projects
Pipeline
Company News
Publicity
Exhibition
Investment Information
Notice
Financial Information
Investment Inquiry
Overall Menu
Company
Company
Introduction
CEO Greeting
Organizational Status
Management Goals
Direction
Products
Diagnostic Kits
Antiviral Agent (VSF)
Products Under
Development
R & D
Antiviral Agent
Infectious Diseases
Research Projects
Pipeline
Company News
Publicity
Exhibition
Investment Information
Investment
Information
Notice
Financial Information
Investment Inquiry
Press Release | ImmuneMed
Press Release
Home
Company News
Company
Products
R & D
Company News
Investment Information
Publicity
Publicity
Exhibition
Press Release
Video Clip
[Journal of Clinical Medicine] COVID-19 Phase 2 Clinical Study Results
Writer
|
ImmuneMed
Views
|
229
Date
|
2022-05-26
Prev 및 Next
Prev
[Heliyon] hzVSF inhibits hepatitis B virus infection by targeting viral cell entry
2022-05-26
Next
[Press Release] ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate
development of the treatment
2021-01-08